Nasonex (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid that binds to intracellular glucocorticoid receptors. This binding alters gene transcription, suppressing the release of inflammatory cytokines and inhibiting activation of inflammatory cells, which together reduce swelling, mucus production, and other signs of nasal inflammation.

The exact dosing regimen for Nasonex is determined by the prescribing healthcare professional. Typically, adults may be instructed to administer one spray into each nostril once daily, but the prescriber will set the appropriate dose and frequency based on the individual’s condition and response.

Safety data for Nasonex in pregnancy are limited, so it should only be used if the potential benefit justifies any potential risk to the fetus. While limited information exists for breastfeeding, the decision to continue treatment should be made in consultation with a healthcare provider.

To order Nasonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nasonex (mometasone furoate) and fluticasone are both intranasal corticosteroids with similar efficacy for allergic rhinitis and nasal polyps. Mometasone has a slightly higher receptor affinity, which may allow effective symptom control at lower spray volumes, but clinical choice often depends on patient preference, device handling, and prescriber experience.

Store Nasonex at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed when not in use, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product after the expiration date printed on the label.

Nasonex is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press down on the actuator while breathing in gently through the nose. The same procedure is repeated for the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, visual disturbances like cataracts or glaucoma, and systemic effects such as adrenal suppression with prolonged high‑dose use. Patients should report any unusual symptoms promptly to their healthcare provider.

Nasonex should not be used by individuals with a known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients who have experienced severe adverse reactions to other intranasal corticosteroids. Consultation with a healthcare professional is essential before initiating therapy.